title: Immunoglobulin E induces VEGF production in mast cells and potentiates their pro-tumorigenic actions through a Fyn kinase-dependent mechanism.
abstract: BACKGROUND
  High concentrations of plasmatic IgE have been related to distinct systemic inflammatory conditions that frequently predispose individuals to hypersensitivity reactions. Although effects of IgE have been suggested to relay on the low-intensity activation of distinct effector elements of the immune system, such as mast cells (MC), experimental evidence on the role of IgE-induced production of inflammatory mediators on specific pathologies is scarce. MC are an important component in tumor microenvironment where they seem to secrete a number of immunomodulatory and angiogenic mediators, such as the Vascular Endothelial Growth Factor (VEGF) by not well-described mechanisms. In this work, we investigated the effect of monomeric IgE (in the absence of antigen) on the production of VEGF in MC, analyzed if monomeric IgE could exacerbate the pro-tumorigenic properties of that cell type and characterized some of the molecular mechanisms behind the effects of IgE on VEGF production and tumor growth.
  
  
  METHODS
  For in vitro studies, murine bone marrow-derived mast cells (BMMCs) were used. Pharmacological inhibitors and phosphorylation of key elements controlling VEGF secretion and protein translation were used to characterize the mechanism of VEGF production triggered by IgE.In vivo, the effect of a single i.v. administration of monomeric IgE on B16 melanoma tumor weight, intratumoral blood vessel formation and tumor-associated MC was assessed in four groups of mice: MC-proficient (WT), MC-deficient (Wsh), Wsh reconstituted with MC derived from WT mice (Wsh Rec WT) and Wsh reconstituted with MC derived from Fyn -/- mice (Wsh Rec Fyn -/-).
  
  
  RESULTS
  Monomeric IgE induced VEGF secretion through a Fyn kinase-dependent mechanism and modulated de novo protein synthesis modifying the activity of the translational regulator 4E-BP1 in BMMCs. In vivo, monomeric IgE increased melanoma tumor growth, peritumoral MC and blood vessel numbers in WT but not in Wsh mice. The positive effects of IgE on melanoma tumor growth were reproduced after reconstitution of Wsh mice with WT but not with Fyn -/- BMMCs.
  
  
  CONCLUSIONS
  Our data suggest that monomeric IgE, in the absence of antigen, induces VEGF production in MC and in vivo contributes to melanoma tumor growth through a Fyn kinase-dependent mechanism.
authors.affiliation: Departamento de Farmacobiología, Cinvestav, IPN, Sede Sur, Calzada de los Tenorios 235, Col. Granjas Coapa, Tlalpan CP 14330, Mexico City, Mexico.
authors.forename: Guillermina Yanek
authors.initials: GY
authors.lastname: Jiménez-Andrade
authors.forename: Alfredo
authors.initials: A
authors.lastname: Ibarra-Sánchez
authors.forename: Diana
authors.initials: D
authors.lastname: González
authors.forename: Mónica
authors.initials: M
authors.lastname: Lamas
authors.forename: Claudia
authors.initials: C
authors.lastname: González-Espinosa
mesh_terms: D000818:Animals; D006801:Humans; D007073:Immunoglobulin E / Q000276:immunology / Q000378:metabolism / Q000494:pharmacology*; D008297:Male; D008407:Mast Cells / Q000187:drug effects* / Q000201:enzymology / Q000276:immunology / Q000378:metabolism*; D008546:Melanoma, Experimental / Q000098:blood supply / Q000378:metabolism / Q000473:pathology; D051379:Mice; D008810:Mice, Inbred C57BL; D018345:Mice, Knockout; D051076:Proto-Oncogene Proteins c-fyn / Q000276:immunology / Q000378:metabolism*; D042461:Vascular Endothelial Growth Factor A / Q000096:biosynthesis* / Q000276:immunology / Q000378:metabolism
chemical_list: D042461:Vascular Endothelial Growth Factor A; D007073:Immunoglobulin E; D051076:Proto-Oncogene Proteins c-fyn
references.citation: Int J Cancer. 1988 Jul 15;42(1):48-52
references.pmid: 2455691
references.citation: Plant Physiol. 2002 Nov;130(3):1102-8
references.pmid: 12427977
references.citation: Mol Cell Biol. 2001 Jun;21(11):3763-74
references.pmid: 11340169
references.citation: Oncol Res. 1998;10(3):133-42
references.pmid: 9700724
references.citation: Inflamm Res. 2011 Jan;60(1):19-27
references.pmid: 20625918
references.citation: Mol Cell Biol. 1998 Jun;18(6):3112-9
references.pmid: 9584152
references.citation: J Exp Med. 2010 Mar 15;207(3):455-63
references.pmid: 20194632
references.citation: APMIS. 2002 May;110(5):355-71
references.pmid: 12076253
references.citation: Pol J Pathol. 2012 Mar;63(1):1-7
references.pmid: 22535614
references.citation: J Immunol. 2002 Dec 15;169(12):6743-52
references.pmid: 12471105
references.citation: Am J Pathol. 2005 Sep;167(3):835-48
references.pmid: 16127161
references.citation: Hum Pathol. 2000 Aug;31(8):955-60
references.pmid: 10987256
references.citation: Immunity. 2001 Jun;14(6):801-11
references.pmid: 11420049
references.citation: J Exp Med. 2003 Jun 2;197(11):1453-65
references.pmid: 12782712
references.citation: Genes Dev. 2001 Aug 15;15(16):2083-93
references.pmid: 11511540
references.citation: J Clin Invest. 1997 Jun 1;99(11):2691-700
references.pmid: 9169499
references.citation: FEBS Lett. 2002 Dec 18;532(3):283-8
references.pmid: 12482580
references.citation: J Immunol. 2004 Oct 1;173(7):4317-23
references.pmid: 15383560
references.citation: J Immunol. 2005 Dec 1;175(11):7602-10
references.pmid: 16301670
references.citation: Nat Immunol. 2002 Aug;3(8):741-8
references.pmid: 12089510
references.citation: Nat Immunol. 2008 Nov;9(11):1215-23
references.pmid: 18936782
references.citation: Nature. 2008 Jul 24;454(7203):445-54
references.pmid: 18650915
references.citation: J Exp Med. 1998 Sep 21;188(6):1135-45
references.pmid: 9743532
references.citation: Blood. 2005 Mar 1;105(5):2059-65
references.pmid: 15542585
references.citation: Proc Natl Acad Sci U S A. 2003 Oct 28;100(22):12911-6
references.pmid: 14569021
references.citation: J Immunol. 2005 Nov 15;175(10):6885-92
references.pmid: 16272347
references.citation: Cancer Immunol Immunother. 1991;34(1):63-9
references.pmid: 1662114
references.citation: Circ Res. 2003 Mar 21;92(5):485-92
references.pmid: 12600879
references.citation: Nature. 2008 Jul 24;454(7203):436-44
references.pmid: 18650914
references.citation: Lancet. 2001 Feb 17;357(9255):539-45
references.pmid: 11229684
references.citation: Cancer Res. 2000 Nov 15;60(22):6253-8
references.pmid: 11103779
references.citation: Biol Pharm Bull. 1995 Feb;18(2):239-45
references.pmid: 7742791
references.citation: Nat Rev Immunol. 2006 Mar;6(3):218-30
references.pmid: 16470226
references.citation: Biochem Biophys Res Commun. 2010 Oct 15;401(2):262-7
references.pmid: 20850416
references.citation: Biochimie. 2000 May;82(5):427-46
references.pmid: 10865130
references.citation: J Biol Chem. 2007 May 11;282(19):14056-64
references.pmid: 17360704
references.citation: J Clin Invest. 2003 Sep;112(5):693-706
references.pmid: 12952918
references.citation: Int J Cancer. 2013 Jun 1;132(11):2492-501
references.pmid: 23161568
references.citation: Allergy Asthma Immunol Res. 2012 Nov;4(6):332-40
references.pmid: 23115729
references.citation: J Am Vet Med Assoc. 1999 Apr 15;214(8):1164-7
references.pmid: 10212675
references.citation: J Biomed Opt. 2011 Jul;16(7):076003
references.pmid: 21806264
references.citation: J Immunol. 2012 Jul 15;189(2):511-5
references.pmid: 22706087
references.citation: Eur J Clin Invest. 2003 May;33(5):420-5
references.pmid: 12760367
references.citation: Ann Allergy Asthma Immunol. 2007 Aug;99(2):102-16; quiz 117-9, 150
references.pmid: 17718097
references.citation: Biochim Biophys Acta. 2012 Jan;1822(1):2-8
references.pmid: 21130163
references.citation: Allergy. 2008 Oct;63(10):1255-66
references.pmid: 18671772
references.citation: J Immunol. 2007 Jan 1;178(1):49-57
references.pmid: 17182539
references.citation: Immunity. 2013 Jan 24;38(1):166-75
references.pmid: 23290520
references.citation: Allergy. 2001 Sep;56(9):813-24
references.pmid: 11551246
references.citation: J Immunol. 2005 Apr 15;174(8):4495-504
references.pmid: 15814670
references.citation: Nat Med. 2003 Jun;9(6):653-60
references.pmid: 12778163